Angiogenesis as an immunopharmacologic target in inflammation and cancer.
Many pathological processes including wound healing, chronic inflammation and cancer require angiogenesis, i.e., the formation of new vasculature in the lesions. Accumulating evidence indicates that angiogenesis is crucial for both chronic inflammation and the growth of malignant tumors with the participation of diverse cytokines, chemokines and growth factors. It is nevertheless believed that differences exist in angiogenesis between cancer and chronic inflammatory diseases. The aim of this review is to outline the characteristics of angiogenesis in chronic inflammation and cancer. A better understanding of the angiogenic processes may facilitate the design of more effective therapies for chronic inflammation and cancer.
Bian
Xiu Wu
XW
Institute of Pathology, Southwest Hospital, Third Military Medical University, Chongqing 400038, PR of China. bianxiuwu@263.net
Chen
Jian Hong
JH
Jiang
Xue Feng
XF
Bai
Jia Si
JS
Wang
Qing Liang
QL
Zhang
Xia
X
D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D042783:Endothelial Cells / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000628:therapy*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000276:immunology* / Q000628:therapy*
D020533:Angiogenesis Inhibitors